Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation

Creative Commons License

Wallentin L., Lopes R. D., Hanna M., Thomas L., Hellkamp A., Nepal S., ...Daha Fazla

CIRCULATION, cilt.127, sa.22, ss.2166-2181, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 127 Sayı: 22
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1161/circulationaha.112.142158
  • Dergi Adı: CIRCULATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2166-2181
  • Anahtar Kelimeler: anticoagulation, apixaban, atrial fibrillation, bleeding, stroke, warfarin, ORAL ANTICOAGULANT-THERAPY, INTENSITY, OUTCOMES, GUIDELINES, DABIGATRAN, MANAGEMENT, REDUCTION, QUALITY, TIME
  • Ankara Üniversitesi Adresli: Evet

Özet

Background-In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and systemic embolism, major bleeding, and mortality. We evaluated treatment effects in relation to 2 predictions of time in therapeutic range (TTR).